Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Biogen Inc. (BIIB) is currently conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL)’. The study aims to evaluate the effects of felzartamab on proteinuria in adults with Immunoglobulin A Nephropathy (IgAN), a condition characterized by protein in the urine due to kidney damage. The primary objective is to assess changes in proteinuria levels from the start of the study to Week 36, with additional focus on kidney function and the safety profile of felzartamab.
The study involves the administration of felzartamab, an intravenous drug, compared to a placebo. Felzartamab is intended to reduce proteinuria and improve kidney function in affected individuals. Participants will receive either the drug or a placebo in a controlled setting.
This interventional study follows a randomized, parallel assignment model with quadruple masking, meaning neither participants nor the research team will know who receives the actual drug or placebo. The primary purpose is treatment-focused, aiming to provide insights into the drug’s efficacy and safety.
The study began on May 8, 2025, with an estimated primary completion date yet to be announced. The last update was submitted on July 15, 2025. These dates are crucial for tracking the study’s progress and anticipating results that could impact Biogen’s strategic decisions.
The outcome of this study could significantly influence Biogen’s market position, particularly if felzartamab proves effective, potentially boosting investor confidence and stock performance. As the biotech industry is highly competitive, positive results could also set Biogen apart from its peers.
The study is ongoing, and further details are available on the ClinicalTrials portal.